Kepler Cheuvreux upgraded Roche to Buy from Hold with a price target of CHF 285, down from CHF 306. The analyst sees “multi-billion potential” for the company’s Alzheimer’s treatment says “potentially extremely potent” weight loss drug data could come this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche receives FDA approval for molecular test to screen blood donors for malaria
- Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
- Rocheâs mixed myasthenia gravis data sending these stocks in opposite directions
- Tourmaline Bio might see weakness today after Roche MG data, says Truist
- Immunovant rallies after Chugai myasthenia gravis study failure
